S&P Global Ratings said that the company’s adjusted debt to a measure of earnings is at a 15-year high.
The deal will give J&J control of nipocalimab, an experimental therapy Momenta is developing to treat autoimmune diseases.
After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
The healthcare giant moved up the coronavirus human clinical trials timeline by about two months.
The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
In a landmark ruling, an Oklahoma judge said the firm's opioid sales practices were false and misleading, endangering the safety of Oklahomans.
The deal is J&J's biggest move into surgical robotics, which "has been a gap for its medical device business."
The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
Deal-makers often don’t consider customers, according to a global branding consultancy. When they do, everybody wins.
The TCJA may force some U.S. companies to reconsider their strategy of shifting profits to affiliates in low-tax jurisdictions.
Johnson & Johnson, Heidrick & Struggles, Amblin Partners, Bruker, Computer Services, Rogers, Outfront Media, LGS Innovations, True Temper Sports
The company's longest-serving finance chief, who presided over three of its largest acquisitions, will be replaced by investor relations VP Joseph Wolk.
